Drug Trial Radar · NCT06690242
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Nov 4, 2024
Primary completion
Aug 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.
Conditions
- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Interventions
MT1013Drug
MT1013 is a novel calcimimetic agent
MT1013Drug
MT1013 is a novel calcimimetic agent
Etelcalcetide HydrochlorideDrug
the already-marketed therapeutic agents
PlaceboDrug
The measure does not contain the active ingredients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with > 30% reduction from baseline in mean iPTH during the efficacy assessment phaseTime frame: Weeks 22 to 27, inclusive
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.